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ABSTRACT 
 Synthetic biology, a field that sits between Biology and Engineering disciplines, 
has come into its own in the last decade. The decreasing cost of DNA synthesis has lead 
to the creation of larger and more complex synthetic gene networks, engineered with 
functional goals rather than simple demonstration. While many methods have been 
developed to reduce the time required to produce complex networks, none focus upon the 
considerable tuning needed to turn structurally correct networks into functional gene 
networks. To this end, we created a Plug-and-Play synthetic gene network assembly that 
emphasizes character-driven iteration for producing functional synthetic gene networks. 
This platform enables post-construction modification and easy tuning of networks 
through its ability to swap individual parts. To demonstrate this system, we constructed a 
functional bistable genetic toggle and transformed it into two functionally distinct 
synthetic networks.  
 Once these networks have been created and tuned at the bench, they next must be 
delivered to bacteria in their target environment. While this is easy for industrial 
	  	   viii 
applications, delivering synthetic networks as medical therapeutics has a host of 
problems, such as competing microbes, the host immune system, and harsh 
microenvironments. Therefore, we employed bacteriophage technologies to deliver 
functional synthetic gene networks to specific bacterial strains in various 
microenvironments.  
We first sought to deliver functional genetic networks to bacteria present in the 
gut microbiome. This allows for functionalization of these bacteria to eventually sense 
disease states and secrete therapeutics. As a proof of concept a simple circuit was created 
using the Plug-and-Play platform and tested before being moved into the replicative form 
plasmid of the M13 bacteriophage. Bacteriophage particles carrying this network were 
used to infect gut bacteria of mice. Infection and functionality of the synthetic network 
was monitored from screening fecal samples. Next, we employed phagemid technologies 
to deliver high copy plasmids expressing antibacterial networks to target bacteria. This 
allows for sustained expression of antibacterial genes that cause non-lytic bacterial death 
without reliance upon traditional small molecule antibiotics. Phagemid particles carrying 
our antibacterial networks were then tested against wild type and antibiotic-resistant 
bacteria in an in vitro and in vivo environment.  
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CHAPTER 1 – GENERAL INTRODUCTION 
1.1 – Synthetic Biology 
 The field of synthetic biology has its roots in the 1970s, when scientists were first 
able to manipulate DNA using a restriction enzyme isolated from H. influenza (Collins; 
Smith et al.; Danna et al.). This discovery allowed scientists to move segments of DNA 
from one organism to another and to even combine DNA fragments in an intelligent and 
predictable way. As more restriction enzymes were characterized, they started to become 
the workhorses that drove many different emerging disciplines in biology, including 
genetics and genetic engineering (Roberts). This ability to easily manipulate DNA 
allowed these disciplines to take large strides in the last few decades, from the 
identification of new genes and genetic markers (Guzman et al.) in genetics to the 
characterization of new metabolomics regulation pathways (Farabaugh) in genetic 
engineering. These fields became increasingly focused upon discovery and 
characterization of new genetic elements and less so on the engineering applications 
available with these discoveries, which allowed for the emergence of synthetic biology.  
 The term synthetic biology first appeared in 1980 when it was used to describe 
bacteria that had been genetically engineered through recombinant DNA technologies 
(Hobom et al.). Since then the term has been used to describe the synthesis of unnatural 
organic molecules as well as research efforts to “redesign life” (Benner; Szostak et al.; 
Brenner et al.). As the field began to take form, it became more challenging to define as it 
encompassed the increasing overlap between biology and engineering (Khalil and 
Collins; Endy). However, at its core, synthetic biology seeks to employ characterized 
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genetic parts to imitate behavior seen in both living and non-living systems using novel 
biological methods. Therefore, it aims to produce complex and controllable functions 
inspired by nature and engineering. My work focuses upon the creation of synthetic gene 
networks from these characterized parts and their delivery to target microenvironments.  
 
1.2 – DNA Assembly 
 As with genetics and genetic engineering, the ability to manipulate DNA through 
the use of restriction enzymes is crucial to synthetic biology. Therefore the overall 
laboratory protocols for introducing DNA fragments to plasmids have changed little in 
the last decade. This technique involves the use of PCR to amplify defined DNA 
fragments as well as add any desired restriction sites, digestion of both the insert DNA 
fragment as well as the vector DNA plasmid with restriction enzymes, and joining via 
ligation enzymes (Sambrook and Russell). This protocol produced many of the first 
synthetic gene networks reported in the field (Gardner et al.; Hasty et al.; McMillen et 
al.). Since then many improvements have been made, including decreasing error rate in 
PCR reactions, improving restriction enzyme functionality, as well as reducing the time 
required to perform the protocol. These improvements allowed for construction of more 
complex and diverse synthetic networks (Kobayashi et al.), which helped move synthetic 
biology out of its infancy.  
 While this method allows for construction of synthetic gene networks, it requires 
stepwise assembly of genes, each with its own cycle of restriction site digestion and 
ligation. Intelligent network design and parallel construction methods can make this 
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stepwise process quicker, but it still can take several days to produce a structurally 
correct synthetic gene network. Newer strategies have focused upon “one-pot” designs 
that allow for addition of multiple gene elements at a time, therefore increasing the 
efficiency of DNA assembly. One such strategy focuses upon designing large regions of 
overlap between neighboring DNA elements and ligation through PCR (Gibson et al.). 
Another strategy employs only one restriction enzyme, which cuts outside of its 
recognition site, to cut multiple fragments of DNA and obtain compatible overlaps for 
ligation. (Engler et al.). These strategies allow for the production of entire synthetic 
networks at one time from parts amplified with PCR.  
 Another strategy that has emerged over the past few years is to simply have a 
synthetic genetic network synthesized by a laboratory. This strategy was extremely 
expensive at its inception, which prohibited many academic laboratories from employing 
this technology to its potential. Recently, however, this technology has become 
increasingly less expensive (Carlson et al.). As costs continue to decrease, due to 
improvements in synthesis techniques, this strategy will doubtless step forward as the 
standard approach. Until then, DNA synthesis provides a stopgap solution for producing 
DNA fragments that are hard to engineer using standard laboratory techniques. 
 While these strategies have allowed for the quick production of structurally sound 
synthetic gene networks, much work still has to be exerted in order to ensure their 
functionality. Repeated iterations of network testing and redesigning are required to 
finally obtain the functionally desired product. This may require several rounds of 
network production, which can be time consuming. To this end, the focus of future 
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design strategies should be on the post-construction tuning of synthetic gene networks, 
without requiring complete reconstruction of the synthetic gene network.  
 
1.3 – Synthetic Gene Networks 
 Living cells are complex organisms that must control a multitude of processes in 
order to thrive. These processes are tightly regulated by various systems, such as 
regulatory proteins, post-translational inhibitors, and other alterations that can tune gene 
expression (Guido et al.; Isaacs et al.; Callura et al.). These regulatory processes allow 
the cell to generate negative feedback loops, feed-forward loops, and other auto-
regulations that can closely resemble basic computational logic or electrical circuits. In 
fact, living cells can be thought as computational systems that execute specific processes 
based upon external inputs and genetic code. Modern molecular cloning methods allow 
us to introduce new code, in the form of synthetic gene circuits (also referred to as 
synthetic gene networks), which allows new processes to be expressed. Many of the first 
synthetic gene circuits were based upon this idea, and therefore expressed logic common 
to computation and engineering (Gardner et al.; Sprinzak and Elowitz).  
 Synthetic gene networks themselves are comprised of several combined DNA 
cassettes, which have been designed to produce a desired output. These cassettes are 
traditionally characterized from naturally occurring organisms and can consist of 
promoters, ribosomal binding sites, genes, regulatory elements, or a range of less 
commonly used elements. Promoters provide the driving force behind synthetic gene 
networks through their ability to initiate transcription (Venter). These promoters can be 
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both positively and negatively affected by various proteins and small molecules, which 
serve as inputs to the synthetic network. Similarly, ribosomal binding sites (RBS) allow 
translation of transcribed elements and production of proteins. These sites can be 
manipulated to obtain a variety of expression levels, based upon the strength of the 
interaction between the RBS and the ribosome (Salis et al.). Gene elements serve as the 
code for protein molecules that act as output or feedback elements that allow for complex 
logic. Genes that code for regulatory elements, such as the tetR gene, cause feedback 
upon the network to regulate logic or activate alternate processes within the synthetic 
gene network (Ramos et al.). Taken together, these elements provide the backbone of 
interactions that can be engineered to produce many different types of complicated logic.  
 Early synthetic gene networks started with simple Boolean logic. One of the first 
constructed gene circuits was a bistable genetic toggle switch (Gardner et al.). This 
circuit stably maintained one of two states and could be toggled from one state to the 
other through addition of inducer molecules. Later synthetic gene networks were built to 
express logic such as if/than statements seen in computer programing or genetic timers, 
which modulated gene expression in a predictable fashion (Ellis et al.). Engineering these 
early synthetic gene networks proved to be very time consuming not only in construction 
but also in the amount of tuning the networks required to become functional. This spurred 
the creation of faster cloning methods as well as the need for modeling methods for 
predicting network behavior so that synthetic networks could be intelligently engineered 
with more complexity (Alper et al; Batt et al; Bornholdt).  
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 These improvements towards building synthetic gene networks, as well as new 
discoveries in cellular regulation, have allowed synthetic biology to produce more 
complicated networks in the past few years. Recent synthetic biology networks have 
allowed bacteria to emulate digital devices by enabling counting (Friedland et al). Other 
developments focus upon providing new methods for gene regulation, including a 
synthetic system for protein degradation (Cameron and Collins). Additionally, the 
discovery of zinc-finger transcription factors in eukaryotes has allowed synthetic biology 
to move easily from bacteria into more complicated cellular systems such as yeast and 
mammalian cells (Khalil et al).  
 While these discoveries in synthetic biology provide a powerful tool for a wide 
host of applications, there are still limitations in both construction and overall function of 
synthetic gene networks that hinder the field’s full potential. The construction of 
synthetic gene networks is limited by the number of characterized genetic parts. With the 
discovery of new cellular pathways and gene regulatory elements, circuits could be 
created to produce more complicated logic. Additionally, current cloning methods do not 
address the need for iterative tuning of synthetic network functionality, which causes 
more time and resources to be spent on development rather than application. Synthetic 
networks can also interfere with host functionality within the cell. Large synthetic 
networks tend to produce many various proteins, which can stress the cell’s ability to 
produce its own proteins required for survival. While this is of little consequence when 
isolated in the laboratory, this stress can produce a survival disadvantage when synthetic 
networks are moved into various in vivo and ecological microenvironments. Solving 
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these limitations would make synthetic biology a powerful tool in industrial (Benner and 
Sismour), ecological (Purnick and Weiss) and medical applications (Ruder et al; Khalil 
and Collins).  
 
1.4 – Bacteriophage Technologies 
 Bacteriophages, which are viruses that have evolved to infect specific strains of 
bacteria, have been used to kill bacteria for centuries. Water from various rivers has been 
documented to cure diseases such as cholera and leprosy (Summers). It wasn’t until the 
late 1800s that the agent in this water was characterized as a bacteriophage. Generally, 
bacteriophages fit into one of two categories. Lytic bacteriophages begin replicating their 
genome and producing viral proteins immediately following infection, which causes lysis 
of the cell membranes and release of mature viral particles (Boyd). In contrast, lysogenic 
bacteriophages do not cause lysis. Instead these bacteriophages deposit their genome, 
which can lie dormant in the cell or even integrate itself into the host genome (Barksdale 
and Arden). Upon induction by an environmental signal, viral genes begin to produce 
bacteriophage particles, which are secreted without lysing the cell.  
 Due to their ability to selectively target strains of bacteria and deposit foreign 
DNA, bacteriophages provide an interesting tool to the field of synthetic biology. 
Introducing a synthetic network into a specific bacteriophage genome would allow for 
network expression in a target bacterial strain. Since most bacteria that would be ideal 
targets for synthetic biology applications reside in various natural microenvironments, 
bacteriophages provide an ideal way to introduce synthetic gene networks without 
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removing these bacteria from the microflora. Recent studies have employed this 
technique to deliver small synthetic networks to combat biofilm production or as an 
adjuvant for traditional small-molecule antibiotics (Lu and Collins; Lu and Collins). 
While these studies mainly focus upon bacterial death in a laboratory setting, few studies 
exist that deliver synthetic gene networks to bacteria already present in their 
microenvironment. This would represent a great leap in both medical and ecological 
fields and would allow for functionalization of these bacteria and expression of 
therapeutic or regulatory molecules under control of engineered logic gates.  
 While this technology has many exciting applications, limitations exist. Care must 
be taken in the selection of bacteriophage, as each bacteriophage strain can only target 
specific bacterial species. This can be an advantage if you want to isolate one or more 
strains from a microenvironment but it becomes increasingly problematic if you want to 
target an entire microflora, such as the gut, which can harbor over 500 species of bacteria 
(Sears). Additionally, the genome of the bacteriophage can become unstable over time, 
due to fluctuations in copy number as it is either replicated or packaged into premature 
viral particles (Smits et al.). This would result in inconsistent expression of a synthetic 
gene network and therefore decrease its functional. Finally, the bacteria themselves can 
become resistant to bacteriophage infection (Labrie et al.). Fortunately, bacteriophages 
have co-evolved with bacteria and tend to target essential targets on the cell surface, such 
as nutrient channels or pili important for survival (Weitz et al). This makes bacteriophage 
resistance either slow to form or transient within the cell.  
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 Recently a new bacteriophage technology was created that addresses the 
limitation of inconsistent network expression. This was accomplished through the 
development of bacterial phagemids (Chasteen et al). This technology focuses upon 
splitting the bacteriophage genome into two separate parts. The first cassette contains the 
entirety of genes required to produce bacteriophage particles, while the second only 
contains the DNA sequence that allows the DNA to become packaged into premature 
bacteriophage particles. This packaging signal is then inserted into any DNA plasmid, 
which allows it to become selectively packaged into viral particles. Using this method, 
synthetic gene networks on plasmids with high copy origins of replication can be 
selectively delivered to target bacteria to ensure consistent network expression.  
 
1.5 – Project Overview 
 This project will focus upon two main avenues of synthetic biology. We will 
begin by exploring new methods for synthetic network construction. We develop a plug-
and-play methodology for molecular cloning that emphasizes post-constructional 
modifications without sacrificing speed of network construction. Using this methodology, 
we produce functional synthetic gene networks and deliver them to target bacteria in 
microbiomes using bacteriophage technologies. We first functionalize the gut microbome 
through bacteriophage delivery of networks expressing styrene monoxygenase or green 
fluorescent protein (GFP). We then track the function of the network by screening fecal 
samples over a one-week period. We also employ phagemid technologies to deliver 
antibacterial synthetic networks to target bacteria in both in vitro and in vivo 
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environments to cause rapid, non-lytic bacterial death without reliance upon traditional 
small-molecule antibiotics. Furthermore we show that this approach results in significant 
bacterial death in both wild type (WT) and antibiotic-resistant bacteria.  
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CHAPTER 2 – A PLUG-AND-PLAY METHODOLOGY FOR THE 
CONSTRUCTION AND MODIFICATION OF SYNTHETIC GENE NETWORKS 	  
2.1 – Overview 
 There are many steps in the process of creating a de novo synthetic gene network. 
First, individual parts must be isolated before they are each added en bloc to a vector 
plasmid. Recently, faster cloning techniques have been developed that target this lengthy 
process by employing PCR or one-pot strategies. While these strategies allow for the 
construction of large synthetic gene networks with incredible speed, they do not enable 
easy post-construction tuning and modification in order to produce a functional circuit. 
This process can require several iterative rounds of cloning, each requiring complete re-
synthesis of a synthetic gene network. Therefore, we designed a construction strategy that 
focused upon post-construction modifications rather than just speed. This would allow for 
easy design and post-construction access to genetic parts and would enable fast 
characterization-driven modifications to produce functional gene circuits. We envisioned 
that this strategy would also allow for repurposing of entire gene circuits into new 
constructs.  
 To this end, we present the “plug-and-play methodology for construction and 
modification of synthetic gene networks”. This system employs a multiple cloning site 
(MCS) comprised of a conserved set of Type IIp restriction sites, a high copy vector 
backbone, and a set of optimized library components. The design of this system ensures 
that restriction sites are maintained during the cloning process, which omits scar 
formation and therefore allows easy post-construction modification. While this 
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methodology employs basic cloning methods to produce functional networks, it can 
easily be combined with PCR or one-pot based cloning methods. A previous version of 
this work was published in Nature Methods titled “Iterative plug-and-play methodology 
for construction and modification of synthetic gene networks” with Kevin D. Litcofsky, 
Raffi B. Afeyan, myself, Ahmad S. Khalil, and James J. Collins (Litcofsky et al.).  
  
2.2 – The Plug-and-play Methodology 
2.2.1 – Multiple Cloning Site 
 Our plug-and-play system was designed to enable rapid and scalable assembly of 
synthetic gene networks through its unique MCS. This employs a set of 31 optimal Type 
IIp restriction enzymes, whose respective restriction sites make up our MCS (Figure 2.1). 
These Type IIp restriction sites each recognize and cut a unique 6 base pair (bp) region of 
DNA and produce either a sticky end, characterized by a 3’ or 5’ overhang of DNA, or a 
blunt end, characterized by an absence of overhang on either strand. These ends can then 
participate in normal molecular cloning techniques in order to ligate DNA segments cut 
with similar enzymes. These 31 restriction enzymes were chosen based upon a specific 
set of criteria in order to ensure speed and ease of construction. Each enzyme is 
manufactured by a single company, NEB (New England Biolabs, MA), and has been 
formulated to have high efficiency in their CutSmart digestion buffer. Where possible, 
high-fidelity (HF) enzymes were chosen due to their increased efficiency and decreased 
star activity. Finally enzymes were chosen to be insensitive to dim/dam methylation, 
which allows for maximum sensitivity in both clonal and experimental strains. The only 
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exception to this methylation insensitivity is XbaI, which was included so the system 
could remain compatible with the BioBricks system (Shetty, Endy et al). A list of all 31 
enzymes is shown in Table 2.1. 
 Each of these restriction enzymes has a single unique restriction site in the MCS 
of our system. These recognition sites are all palindromic and non-degenerate, in order to 
reduce the likelihood of unexpected sites resulting during the planning or cloning 
process. A 6 bp region of spacing DNA separated neighboring restriction sites. Since 
some restriction enzymes require a certain number of DNA residues on either side of the 
recognition site in order to function, this spacing DNA allows for unique double digestion 
neighboring sites without causing interference.  
2.2.2 – Vectors 
 After designing this large MCS, we next built a set of backbone vectors that 
would allow for easy use of this system. To this end, we based our cloning vectors on the 
well-characterized pZE vector system developed by Lutz and Bujard (Lutz and Bujard). 
These vectors contain the high copy E. coli origin of replication, colE1, as well as a 
resistance gene for clone selection. While this vector system has been widely used in 
common molecular cloning techniques, several modifications were made to produce our 
plug-and-play system. In order to ensure the uniqueness of each restriction site in our 
MCS, the entire plasmid was optimized to remove any extraneous restriction sites. This 
was accomplished via random mutagenesis for the origin of replication as well as the 
spacer regions of DNA between the origin, resistance cassette, and MCS. Since the 
resistance cassette produces resistance proteins, optimization was accomplished through 
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codon substitution to ensure proper protein sequence while removing unwanted 
restriction sites. Each optimized cassette was tested to ensure these mutations did not 
produce a decrease or loss of function. With these modifications, three cloning vectors 
were produced that employ optimized versions of the high copy colE1 origin of 
replication and either ampicillin, kanamycin, or chloramphenicol resistance genes. These 
cloning vectors were named pKE1MCS, pKE2MCS, and pKE3MCS respectively.   
2.2.3 – Parts Library 
 With the production of cloning vectors that were optimized for use with the 
designed MCS, we next selected a set of 26 well characterized and commonly used 
genetic components shown in Table 2.2. These components (referred to as “parts” from 
here on) were then optimized for use with our MCS in order to remove extraneous 
restriction sites. This was accomplished through random mutagenesis for promoters and 
other regulatory elements and codon substitution for genes. Once these parts were 
optimized in silico, they were created either by PCR, site directed mutagenesis, or by de 
novo synthesis (DNA 2.0, Inc). Genes were designed to contain the ssrA degradation tag 
(Gottesman et al), which is used in certain gene circuits to ensure network balance. 
Including this degradation tag in all genes in the library allows for the flexibility to PCR a 
gene with or without this tag. Once all 26 parts were optimized, each was characterized to 
ensure proper function (Figure 2.2, 2.3, 2.4). Specific genetic circuits were created in 
order to test promoters, regulatory elements, and other parts such as terminators. After 
ensuring their functionality, each part was placed into a library plasmid labeled pKli000 
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with PvuII sites flanking the part to facilitate digests or PCR design. The library was then 
transformed into common E. coli clonal strains such as NEB Turbo, DH5-α, or NEB-10β.  
2.2.4 – General Usage 
 Constructing synthetic gene networks with this methodology is straight forward 
due to the creation of our optimized vectors and parts library (Figure 2.5). Desired 
components are assigned to a “slot”, a pair of adjacent restriction sites within the MCS. 
Library parts are then amplified via PCR from their respective library plasmid in order to 
add the appropriate restriction sites. After PCR, both the amplified part and vector 
plasmid are each digested with the appropriate restriction enzymes. Digests are then 
purified by gel electrophoresis or by column filtration and then are ligated together at the 
appropriate molar ratio. Resulting ligated plasmids are then transformed into the target E. 
coli strain. Clones from this process are then tested by digestion and gel electrophoresis 
for appropriate DNA weights, PCR, functional screening, or by sequencing. This process 
is then repeated using the newly formed plasmid until all parts are incorporated into the 
MCS and the network is constructed. Construction can be performed in a parallel process 
in order to minimize cloning steps. Once the complete synthetic network has been 
incorporated into the desired plasmid, many, if not all, of the components can be changed 
at will. Since restriction sites between network parts are maintained, individual 
components as well as large portions of the network can be removed via restriction 
enzyme digest. This piece is then separated from the vector via gel electrophoresis and 
the vector is purified and reused for the next round of cloning.  
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Figure 2.1 – Multiple Cloning Site.  
DNA sequence of the MCS common to all vector plasmids of the plug-and-play methodology.  
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Enzyme Recognition Site 
AatII GACGT|C 
AclI AA|CGTT 
AflII C|TTAAG 
ApaLI G|TGCAC 
AvrII C|CTAGG 
BamHI-HF G|GATCC 
BsrGI T|GTACA 
EagI-HF C|GGCCG 
EcoRI-HF G|AATTC 
EcoRV-HF GAT|ATC 
HindIII-HF A|AGCTT 
KasI G|GCGCC 
KpnI-HF GGTAC|C 
MfeI-HF C|AATTG 
MluI A|CGCGT 
NcoI-HF C|CATGG 
NdeI CA|TATG 
NheI-HF G|CTAGC 
PciI A|CATGT 
PstI-HF CTGCA|G 
PvuII-HF CAG|CTG 
SacI-HF GAGCT|C 
SacII CCGC|GG 
SalI-HF G|TCGAC 
ScaI-HF AGT|ACT 
SpeI A|CTAGT 
SphI-HF GCATG|C 
SspI-HF AAT|ATT 
XbaI T|CTAGA 
XhoI C|TCGAG 
XmaI C|CCGGG 
  
 
Table 2.1 Plug-and-play restriction enzymes.  
A list of restriction enzymes used in the plug-and-play methodology. All enzymes have a high activity in 
the CutSmart digestion buffer from NEB. High-fidelity enzymes are used where available. Cleavage sites 
are designated by the “|” symbol.  
 
	  	  
18 
 
Component Length(bp) Library Plasmid Type 
LuxR 756 pKLi049 Gene (Activator) 
AraC_JK_LAA 879 pKLi051 Gene (Activator) 
ECFP-LAA 759 pKLi015 Gene (Fluorescent Reporter) 
EYFP-LAA 759 pKLi013 Gene (Fluorescent Reporter) 
GFPmut3b-LAA 756 pKLi011 Gene (Fluorescent Reporter) 
mCherry-LAA 750 pKLi037 Gene (Fluorescent Reporter) 
mCherry-LCOpt-LAA 750 pKLi056 Gene (Fluorescent Reporter) 
flpE-LAA 1305 pKLi025 Gene (Recombinase) 
cI-LAA 753 pKLi021 Gene (Repressor) 
lacI-LAA 1122 pKLi017 Gene (Repressor) 
tetR-LAA 663 pKLi019 Gene (Repressor) 
LuxI_RSR 618 pKLi047 Gene (Quorum Sensing) 
PBAD 286 pKLi034 Promoter 
Plac/ara 483 pKLi053 Promoter 
PLs1con 558 pKLi031 Promoter 
PLtetO 74 pKLi030 Promoter 
Plux 219 pKLi055 Promoter 
Plux/cI 97 pKLi048 Promoter 
PmgrB 543 pKLi054 Promoter 
Ptrc2 75 pKLi032 Promoter 
T0 123 pKLi027 Transcriptional Terminator 
T1T2 231 pKLi028 Transcriptional Terminator 
Spacer-50bp 50 pKLi057 Spacer 
Spacer-100bp 100 pKLi058 Spacer 
Spacer-250bp 250 pKLi059 Spacer 
Spacer-500bp 500 pKLi060 Spacer 
 
Table 2.2 Optimized Parts for the Plug-and-play System.  
A list of parts that have been optimized for use with the plug-and-play methodology. Lengths and plasmid 
names are included.  
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Figure 2.2 Characterization of Optimized Promoters.  
Optimized promoters were tested along side their “WT” versions as a control. Promoters that did not need 
to be optimized for compatibility were not tested.  
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Figure 2.3 Characterization of Optimized Transcription Factors.  
Simple test networks were built in order to test our optimized transcription factors. Transcription factors 
were put under regulation of a magnesium sensitive promoter and transcription factor regulation was tested 
through expression of GFP.  
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Figure 2.4 Characterization of Optimized Terminators and Reporters. 
Optimized terminators were tested by placing a terminator between polycistronic reporter genes. Optimized 
reporters were tested by simple expression and fluorescence screening.  
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Figure 2.5 Overview for the Plug-and-play Methodology. 
 (a) The different components of the Plug-and-play system: Cloning vectors with our optimized MCS, 
optimized component library, and constructed networks. (b) The basic method for construction of synthetic 
gene networks. Genetic parts are purified via PCR, digested along with the desired vector, and ligated. 
Resulting clones from the ligation are then transformed and tested. This process is then iterated until the 
network is complete.  
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2.3 – Strengths of the Plug-and-Play Methodology 
2.3.1 – Building a Toggle Switch 
To demonstrate the strengths of the plug-and-play system, we decided to 
recapitulate the original genetic toggle switch (Gardner et al.). This synthetic gene 
network was one of the first major synthetic networks and has been well characterized 
since its creation. Since genetic switches require a balance between several components 
within the network and therefore require careful post-construction tuning, we thought it 
an appropriate synthetic gene network to demonstrate the strengths of the plug-and-play 
methodology.  
Our genetic toggle was inspired by the pIKE107 constructed plasmid described in 
the original toggle paper. Two small molecules, IPTG and aTc respectively, control two 
mutually repressive sides of the toggle, which is characteristic for this network. While 
other versions of this toggle employ temperature to induce network expression, we 
decided on chemical inducers to allow for increased control of expression. Additionally, 
we modified the original circuit design to include an additional fluorescent reporter in 
order to remove uncertainty in toggle state and allow for better network characterization. 
All genetic components used in the construction of this network were taken from our 
optimized parts list. Therefore our initial design included two optimized promoters, PLTetO 
and PLlacO, two optimized repressors, lacI and tetR, and two optimized fluorescent 
reporters, GFPmut3b and mCherry.  
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Using these genetic parts, the circuit was planned out in a polycistronic fashion. 
Each side of the toggle was orientated away from the other in order to minimize any read 
through error, which would destabilize the circuit. A synthetic RBS for each gene was 
designed using the RBS Calculator designed by the Salis Lab (Salis) in order to produce 
predictable expression levels regardless of gene location. Each genetic part was assigned 
to a unique location in our MCS to produce the first version of our toggle, which was set 
up in the following order. The first side was made up of PLTetO-RBS1-lacI-RBS2-
GFPmut3b, while the opposite side was set up PLlacO-RBS3-tetR-RBS4-mCherry.  
While this version of our toggle was structurally correct, we found that several 
post-constructional modifications needed to be made to arrive at a functional product 
(Figure 2.6). The first version of the toggle was unresponsive to either inducer, possibly 
due to poor transcription of our genetic elements. To solve this, we added an additional 
promoter to each node in order to convert the toggle from a polycistronic to a 
monocistronic design. This second version exhibited strong GFP expression with 
induction of aTc, but was unable to reliably switch to its mCherry state upon IPTG 
induction. This lack of switching suggested poor promoter driven transcription of both 
the tetR and mCherry genes. Since our optimized component library contained multiple 
lacI-repressed promoters, we swapped the PLlacO promoter for the Ptrc-2 promoter. This 
third version of our toggle proved to be a functional circuit, with the ability to stably 
maintain either GFP or mCherry state and quickly switch between the two. While this 
version was functional, further tuning was needed to arrive at the ideal network. By 
performing random mutagenesis upon the Shine-Dalgarno sequence in RBS3, which 
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controls the tetR translation rate, a fully balanced network was created. This network 
provided for fast switching of genetic states, which is the ideal function for a genetic 
toggle (Figure 2.7). It is worth noting that the construction effort to produce the initial 
version of our toggle took five days using a parallel approach, while tuning took two 
separate three-day cycles to finalize the network. While this construction is only slightly 
slower than previously mentioned “one-pot” methodologies, functional products are 
produced at a much faster pace.  
2.3.2 – Repurposing Circuits 
Another strength of our method is its ability for large-scale reconstruction and 
design changes for existing networks. Repurposing pre-constructed synthetic networks 
can save time compared to de novo construction and  ensures that some portion of the 
circuit has already been tuned, which decreases post-construction modifications. 
Therefore, we used our pre-tuned and functional genetic toggle to quickly construct two 
functionally distinct feed-forward networks of different sizes.  
Feed-forward loops (FFLs) are a common regulatory motif found in nature 
(Mangan et al.). They function by producing downstream gene expression, which feeds 
back upon an earlier node thereby enhancing further production of downstream elements. 
FFLs can result in a variety of behavior such as delaying or pulsing gene expression, 
depending on the functional design of the network. By employing some of the gene 
regulation common to our genetic toggle switch, we designed a 3- and 4-node FFL 
(Figure 2.8). These FFLs are composed of both a direct and an indirect path to our final 
gene output, mCherry. Addition of multiple nodes into the indirect path increases the 
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delay in gene expression. Therefore we expect our 3-node FFL gene circuit to activate 
before the 4-node FFL circuit.  
We built the FFLs using a parallel construction strategy that employed network 
motifs found in our genetic toggle in order to reduce the overall construction time. In 
total, it took two insertions and two substitutions to arrive at the 3-node FFL from the 
toggle and an additional insertion and two substitutions to produce the 4-node FFL. By 
using our cloning methodology we were able to produce these distinct networks from our 
pre-constructed toggle in four and five days respectively (Figure 2.9).  
Although construction of these FFLs was hastened through use of our genetic 
toggle, additional tuning still needed to occur before the networks functioned as desired. 
Our first version of the 3-node FFL circuit was found to have a high expression rate 
regardless of inducer concentration. This suggested that its promoter was either leaking 
through its regulation by the tetR protein or expression of tetR was not adequately strong 
enough to provide sufficient repression. To fix this we altered the RBS strength of the 
tetR gene to allow for stronger protein translation. This alteration was sufficient to allow 
for proper network function and was named pKDL106. Due to the alteration needed to 
tune our 3-node FFL, we preemptively modified the 4-node FFL with a new RBS. Even 
with this modification the 4-node FFL was not fully functional. We suspected the 
problem was isolated to the portion of the network that was distinct from our 3-node 
design and therefore altered expression levels in this section through random mutagenesis 
of the Shine-Dalgarno sequences. These changes were then screened for functionality and 
the resulting clone was sequenced. This functional 4-node FFL was named pKDL108. 
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These final networks, along with a one-node control, were grown in their respective 
conditions (arabinose for the 3-node FFL and arabinose/AHL for the 4-node FFL) and 
were induced for network expression by the absence of Mg2+. Fluorescence 
measurements were taken every hour during an 8-hour time course (Figure 2.10). Each 
network functioned in a distinct manner. The one-node circuit immediately responded to 
its inducer, whereas the 3- and 4-node FFLs required a longer induction time in order to 
produce its final output. The addition of an extra node to produce the 4-node FFL 
increased this delay, which corresponds to its designed function.  
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Figure 2.6 – Construction of the Genetic Toggle Switch.  
Construction of the genetic toggle was accomplished through a 5-day parallel design cycle. 
Characterization of the structurally correct network allowed for multiple iterations of tuning, creating its 
functional end result Toggle v4.  
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Figure 2.7 – Final Toggle Switching and Bistability.  
The final toggle network was induced to either a GFP or mCherry producing state. After washing out any 
residual inducer, the toggle was then switched to its opposite state over the following 5 hours and 15 
minutes, after which inducers were removed. Bistablity is shown approximately 16.5 hours later. All 
samples were screened on a FACS.  
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Figure 2.8 – Synthetic Gene Network Design of 3- and 4-node FFLs.  
Network map for the final 3- and 4-node FFL networks along with inducer and regulatory schemes.  
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Figure 2.9 – Construction Scheme for Repurposing Genetic Networks.  
A 5-day construction scheme for repurposing the genetic toggle switch into a 3- and 4-node FFL through 
parallel network modifications.  
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Figure 2.10 – FFL Network Characterization.  
Cells carrying either a 1-, 3-, or 4-node feed forward loops were induced through MgCl2 absence. Six hours 
after induction, MgCl2 was reintroduced to the media at a final concentration of 50 mM in order to stop 
induction. Cells were measured on a flow cytometer for mCherry fluorescence at one-hour intervals over 
the course of 8 hours. Each measurement was preformed in triplicate with 10,00 events per measurement 
per time point. 
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2.4 – Impact and Discussion 
 This cloning method provides a much-needed strategy for construction and tuning 
of synthetic genetic networks. By focusing on the back end of the construction process 
and employing an optimized backbone, containing a large MCS, high copy origin of 
replication, and resistance gene, as well as optimized genetic parts, this processes allows 
one to rapidly build and tune synthetic networks. Additionally, this method can be 
combined with “one-pot” construction strategies, such as Gibson and Golden Gate 
cloning methods, while still allowing easy tuning and repurposing of circuits.  
 Synthetic biology is currently poised to make large applicational strides in a 
number of fields. Recent discoveries of new regulation schemes and novel genetic parts 
have allowed for the creation of more complicated synthetic gene networks and therefore 
more complex applications. Currently, however, the field of synthetic biology relies 
heavily upon construction and test cycles to achieve functional networks. In fact, these 
cycles produce such a time burden that the pace of progress in the field has been severely 
hampered. Ideally a synthetic biologist will not have to be limited by the pace of genetic 
network fabrication, but instead will focus upon analyzing circuit behavior in order to 
drive design changes. While wholesale synthesis of genetic networks is becoming a more 
and more feasible solution for circuit construction, this methodology, combined with 
“one-pot” strategies, allows for quick construction and behavior driven tuning of 
synthetic networks. Until full synthesis techniques become financially viable, this 
methodology will reduce the construction burden and allow more time for precise tuning 
and testing of complex and innovative networks.  
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Chapter 3 – FUNCTIONALIZATION OF ENDOGENOUS BACTERIA 	  
 3.1 – Overview 
 While much time and effort has been put into the construction and 
characterization of synthetic gene networks, the true goal of synthetic biology lies in 
providing real world applications that exist outside of the laboratory. In order to 
accomplish this, once a synthetic gene network has been created and tuned it must be 
delivered to its target microenvironment. While this can be easy for certain industrial 
applications (Khalil and Collins), it becomes increasingly difficult when gene networks 
must be delivered to medical or ecological environments (Ruder et al.). Delivery systems 
must combat with harsh microenvironments, host immune systems, as well as competing 
microbes in order to simply arrive at their target location. Once delivered, synthetic gene 
networks must then function properly in a complex environment without producing 
unwanted detriments.  
 Of particular interest for synthetic biology are medical applications. A wide host 
of bacterial microbiomes exists in and on the human body (Sears; Tuohy et al.; 
Turnbaugh et al.). The gut and skin microbiome have been previously shown to be very 
important for maintaining human health (Kinross et al.; Grice, E and Segre, J).  
Delivering a synthetic gene network to these microbiomes would allow for a gain-of-
function or functional enhancement for healthy bacteria, or specific targeting and 
elimination of unwanted bacteria.  
 We sought to employ lysogenic bacteriophage technologies to enable delivery of 
synthetic gene networks to gut bacteria. This would allow for the functionalization of 
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these bacteria to be used as medical therapeutics or sensors for disease (Figure 3.1). 
Using the plug-and-play methodology, we first constructed three synthetic networks that 
produce distinct enzymes, which convert indole to indigo, as well as one network that 
produce the fluorescent molecule, GFP. Indole is a common bacterial signaling molecule 
in the gut microbiome that can be converted to indigo, a blue-purple dye, through a series 
of oxidative steps (O’Connor et al.). Our most effective networks were then moved into 
the M13 bacteriophage genome and bacteriophage particles carrying our network was 
tested on E. coli bacteria in vitro as well as bacteria in the gut of mice in an in vivo 
delivery model. A summary of this work was published as a US Patent application 
(US20150004705 A1) on January 1st, 2015. 
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3.2 – Delivery of Indigo Producing Networks 
3.2.1 – Construction and Screening of Test Networks 
Due to the relatively high concentrations of indole present in the gut (Smith and 
Macfarlane), we designed test networks expressing oxidative enzymes that convert this 
indole to the blue-purple dye indigo. As indigo is small enough diffuse through the cell 
membrane (Ensley et al.), in vivo monitoring of these networks can be accomplished 
through colorimetric screening of fecal samples. Each network was designed to be either 
constitutive, using the PLtetO promoter, or inducible, using the arabinose sensitive PBad 
promoter (Figure 3.2). These promoters drove expression of an indigo producing enzyme 
with an appropriate RBS and terminator.  
Three indigo producing enzymes were chosen from the literature for their ability 
to rapidly produce indigo from indole. Styrene monooxygenase (StyAB) is an extremely 
efficient two-component enzyme that oxidizes indole to produce indigo through an 
indoxyl intermediate (O’Connor et al.). Expressing only one component of this enzyme 
(StyA) also produces indigo, although through a soluble 2-oxindole intermediate 
(O’Leary et al.). This intermediate relies upon external oxidative forces to produce 
insoluble indigo and therefore is much less efficient than its full StyAB version. The final 
enzyme tested was the toluene dioxygenase enzyme characterized in Pseudomonas 
bacterial strains (Wackett and Gibson). This enzyme converts indole to an indolediol 
intermediate through several oxidative steps before finally producing indigo. Due to the 
unpredictable microenvironment of the gut, these three enzymes were chosen since they 
each produce indigo from indole through distinctly different intermediates (Figure 3.3).  
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To create our indigo networks, we employed the plug-and-play construction 
methodology described by Litcofsky et al. The three enzymes were amplified through 
PCR from plasmids containing the enzyme or from gene synthesis products (Genewiz) 
and desired restriction sites and synthetic RBS were added to the appropriate 5’ and 3’ 
ends. Our synthetic RBS was designed to produce a high translation rate since 
overproduction of indigo was our design goal. Promoters and terminators were amplified 
using PCR from the appropriate library plasmids to add the appropriate restriction 
enzymes. These parts were then added to the MCS of the pKE2MCS cloning vector in a 
stepwise fashion to create the inducible and constitutive networks expressing for StyAB, 
StyA, or Toluene Dioxygenase (designated pRJK029, pRJK030, pRJK031, pRJK032, 
pRJK025, and pRJK026 respectively). These networks were then transformed into the 
bacterial test strain, mgpro, which allows for regulation of the PLtetO promoter that is 
otherwise constitutive in WT E. coli.  
To test the functionality of these networks, bacterial cells containing the network 
were grown in M9 minimal media that was supplemented with physiological levels of 
indole (Smith and Macfarlane). Since normal Luria Broth (LB) media contains 
tryptophan, which can easily be converted to indole by bacteria, M9 media was used and 
supplemented with amino acids lacking tryptophan. After a few hours of growth (until an 
OD ~ 0.3), the synthetic gene networks were induced with either arabinose or aTc for the 
PBad and PLtetO promoters respectively. Indigo production was monitored calorimetrically 
for absorbance at 610 nm (Figure 3.4).  
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3.2.2 – Construction and Screening of Bacteriophage Networks 
Due to the strength of the styrene monooxygenase (StyAB) networks (pRJK029 
and pRJK030), we moved these selected circuits into a bacteriophage delivery system. 
The M13mp18 replicative form plasmid for the M13 bacteriophage was obtained from 
NEB. This plasmid was previously modified to include a small MCS, into which we 
cloned our functional indigo producing networks. Bacteriophage particles were purified 
from plaques containing these networks and tested on EMG2 E. coli bacteria (Figure 3.5). 
Arabinose was included as needed to activate the PBad promoter in our inducible network, 
whereas the PLtetO promoter is constitutive in this cell type. Our StyAB test networks 
were included as a positive control. To prove that expression of our inducible indigo 
producing bacteriophage network could be modulated by arabinose concentration, we 
preformed an arabinose dose dependence curve on EMG2 bacteria infected with the 
inducible StyAB expressing bacteriophage (Figure 3.6).   	  
3.2.3 – In vivo Network Delivery 
With the production of engineered bacteriophage particles that deliver an indigo 
producing network to target bacteria, we sought to test a delivery system in an in vivo 
system. These bacteriophage particles could be given orally to mice in order to 
functionalize the E. coli bacteria already present in their gut microbiome. To this end, we 
employed a gnotobiotic mouse model (Samuel and Gordon). This model allowed us to 
colonize mice with specific strains of bacteria in order to maximize our chances for 
successful delivery of our synthetic gene networks. While this model provides a gut 
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microbiome that is quite distinct from that found in WT mice, it provides a good proof-
of-concept model from which future experiments on WT mice can be derived.  
In our model, newborn mice were born into a sterile environment. Once the mice 
were of an appropriate age, their intestines were seeded through gavage with either 
unmodified EMG2 E. coli bacteria or EMG2 bacteria carrying our indigo test networks as 
a positive control. After 2-3 days, the gut microbome was stably colonized with the 
bacterial strain of choice. Mice colonized with unmodified EMG2 were then given either 
bacteriophage particles carrying our constitutive synthetic network or LB (negative 
control) via gavage on days 0 and 3 of the experiment. Mice colonized with our positive 
control EMG2 bacteria were also given LB by gavage on days 0 and 3 of the experiment. 
Fecal samples from the bacteriophage, positive control, and negative control group were 
screened for indigo production daily (Figure 3.7).  
Unfortunately, the data showed no signs of either bacteriophage infection or 
functionalization of the gut microbiome. Bacteria recovered from the fecal samples were 
analyzed for plasmid DNA and bacteriophage DNA through either pure DNA yield, 
double digest for expected DNA weights on gel electrophoresis, or PCR using primers 
designed to amplify our synthetic gene circuit. Isolating DNA from bacteria from positive 
control, negative control, or bacteriophage mice revealed the presence of plasmid DNA in 
the positive control, but no plasmid DNA in bacteriophage samples when compared to 
the negative control and a frozen stock control. PCR using primers designed to bind to 
our synthetic network did not produce any functional product (Figure 3.8). Using the 
plasmid DNA isolated from our positive control samples, we used restriction enzymes to 
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digest our indigo producing network from the backbone vector. This should produce two 
different sizes of DNA, which can be isolated using gel electrophoresis. Digestion with 
these enzymes, however, only produced a single DNA size (Figure 3.9). This suggests 
that the bacteria in the gut are mutating our synthetic gene network to reduce expression 
of the network and therefore decrease metabolic load. Sequencing of the plasmids 
isolated from the positive control fecal samples showed mutations within our PLtetO 
promoter, which would turn off expression of our network.  
We therefore switched to our inducible bacteriophage network and added 
physiological levels of indole to the drinking water of mice. The levels of indole in the 
mouse gut could perhaps be much lower than in the human gut, so we therefore sought to 
rectify this discrepancy through direct addition of indole. This, however, also provided no 
positive results. Since this can be due to a wide host of possibilities including down 
regulation of the F pilus (the bacteriophage binding site), further mutation of our 
network, and metabolic alteration of our target substrate (indole) or inducer (arabinose), 
we decided to simplify our synthetic gene network. Instead of delivery of a constitutive 
or inducible network expressing a large enzyme, which relies upon high levels of 
substrate, we next designed a simple constitutive GFP producing network.  	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Figure 3.1 – Functionalization of Endegenous Bacteria Overview.  
(a) Bacteriophage particles, which carry a synthetic gene circuit, are given to mice via gavage in order to 
cause infection and functionalization of the gut microflora. (b) A proof of concept network, which 
expresses enzymes converting indole to indigo, should provide a functional output in the fecal samples of 
infected mice. Future networks can be induced through inducers or disease states in order to secrete 
therapeutics or signaling molecules.  	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Figure 3.2 – Network Architecture of Indigo Producing Networks.  
The general structure for our indigo producing networks employs either an inducible or constitutive 
promoter, which drives expression of an indole-converting enzyme with a synthetic ribosomal binding site. 
A terminator is included to ensure proper control of our network.  
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Figure 3.3 – Enzymatic Conversion of Indole to Indigo. 
The overview for converting indole to indigo by the enzymes StyAB, StyA, and TODC1C2AB through 
various intermediaries.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enzymatic	  Conversion	  of	  Indole	  to	  Indigo	  Through	  Various	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StyAB:	  Indole	  à	  Indole	  Oxide	  à	  Indoxyl	  (soluble)	  à	  Indigo	  (insoluble)	  	  
StyA:	  Indole	  à	  Indole	  Oxide	  à	  2-­‐oxindole	  (soluble)	  à	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TODC1C2AB:	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  à	  	  à	  	  à	  Indolediol	  (soluble)	  à	  Indigo	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Figure 3.4 – Indigo Production of Test Networks.  
(a) Test networks in mgpro E. coli cells grown with 400 uM indole were induced with either .01% 
arabinose or 0.5 ug/mL aTc to induce enzymatic expression of the network. Cells were tested for indigo 
production each hour for 4 hours and once overnight at 18 hours post induction. (b) Liquid cultures 
expressing an indigo producing network turn a deep blue-purple color in comparison to an uninduced 
culture. Isolating indigo through DMSO solubilization shows a similar blue color in induced samples.  
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Figure 3.5 – Indigo Production of StyAB Bacteriophage Networks.  
Bacteriophage particles carrying either an inducible or constitutive StyAB network were used to infect 
EMG2 bacteria. The inducible networks were activated through addition of .01% arabinose. Cells were 
grown in 300 uM indole.  
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Figure 3.6 – Dose Dependence of the Inducible StyAB Bacteriophage Network.  
Bacteriophage particles carrying the inducible StyAB network were used to infect EMG2 bacteria. The 
inducible network was activated with the addition of between 0.025-0.8% arabinose to show dose 
dependence. Cells were grown in 300 uM indole.  
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Figure 3.7 – In Vivo Bacteriophage Delivery of StyAB Network Results.  
Fecal samples from positive control, negative control, and bacteriophage test mice were screened for indigo 
production over a 10-day period. Fecal samples were dissolved in DMSO to solubilize trapped indigo and 
centrifuged to purify the sample. Supernatants were then read on a plate reader at 610 nm for indigo 
absorbance.  
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Figure 3.8 – DNA Recovery and Screening from in Vivo Samples.  
(a) DNA was isolated via miniprep from bacteria recovered from positive control, negative control, and 
bacteriophage test fecal samples. DNA yields are reported over a 4-day period along with a frozen stock 
control. As the bacteriophage yields are significantly similar to both the negative and frozen stock controls, 
no bacteriophage plasmids or infection were seen in these samples. (b) The DNA isolated from 
bacteriophage and negative control samples were PCR amplified using primers designed to bind to the 
StyAB network. No PCR product bands are seen in the bacteriophage samples, which suggest that no 
infection occurred in these samples.    
 
 
 
 
 
 
 
 
EMG2 Frozen Stock Control: 43.7 ng/uL 
 Positive Control Bacteriophage Negative control 
Day 1 75.3 ng/uL 25.8 ng/uL 14.5 ng/uL 
Day 2 72.7 ng/uL 26.2 ng/uL 33.6 ng/uL 
Day 3 104.6 ng/uL 35.4 ng/uL 30.8 ng/uL 
Day 4 90.4 ng/uL 42.0 ng/uL 32.4 ng/uL 
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Figure 3.9 – Positive Control Network Screening.  
(a) DNA isolated from positive control fecal samples was double digested in order to isolate the StyAB 
network from the vector backbone. Instead of two separate bands, only a single band was seen suggesting 
mutation in the network. (b) Sequencing of the StyAB network showed large mutations to the promoter 
region. Red letters designate tet binding sites in the promoter while blue letters designate known restriction 
sites. 
Day 1 Day 2 Day 3 Day 4 
PLtetO Promoter Expected Sequence: 
GACGTCTGTGCAAGTACTTCCCTATCAGTGA
TAGAGATTGACATCCCTATCAGTGATAGAGAT
ACTGAGCACATCAGCAGGACGCACTGACCC
AGCTGAAGGATTAAGGAGGTAGCATGC 
!
PLtetO Promoter Sequencing Results: 
GACGTCTGTGCAAGTCTGGGTCAGTGCGTC
CTGCTGAAGGATTAAGGAGGTAGCATGC!
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 3.3 – Delivery of GFP Producing Network 
3.3.1 – Construction and Screening of Test Networks 
In order to create a constitutive GFP network, we repurposed a network produced 
during the testing of our optimized parts for our plug-and-play methodology. This 
network employed the Ptrc2 promoter, which functions similar to PLtetO but lacks the 
repetitive DNA sequence that may have led to the mutations seen in vivo. This new 
promoter drives constitutive expression of our optimized GFP gene in WT bacteria, but is 
regulated in our test strain mgpro through repression by the lacI gene. This network was 
tested in our test strain, mgpro, alongside similar networks that employ either the 
optimized or WT PLlacO promoter. Each of these networks was activated through addition 
of the IPTG inducer at various doses, which drove expression of the optimized GFP gene 
(Figure 3.10). We found that the Ptrc2 promoter responded slower to its inducer, but had a 
higher expression compared to the PLlacO promoters. This is ideal, since it would allow for 
maximum expression in our target WT bacteria.  
3.3.2 – Construction and Screening of Bacteriophage Networks 
We next moved this functional GFP producing network into the m13mp18 
replicative form bacteriophage plasmid. The network was amplified using PCR to add the 
desired restriction sites to the 3’ and 5’ ends, which allowed it to be ligated into the MCS 
of the bacteriophage plasmid. Bacteriophage particles from the resulting plaques were 
purified and tested against our target E. coli bacteria for GFP expression (Figure 3.11). 
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With the success of this bacteriophage network, we next tested our GFP producing 
bacteriophage particles in our in vivo model.  	  
3.3.3 – In vivo Network Delivery 
As with our in vivo indigo producing experiments, we used gnotobiotic mice that 
were colonized with our target E. coli bacteria to provide a proof of concept for in vivo 
delivery. Mice were colonized either by EMG2 bacteria alone or with EMG2 bacteria 
carrying the GFP test plasmid as a positive control. On days 1 and 3 after colonization, 
mice were either given a gavage of bacteriophage particles carrying the GFP producing 
network or LB as a control. Bacteria recovered from fecal samples were then screened for 
GFP production daily (Figure 3.12). Our positive control group, which was colonized 
with bacteria already containing our GFP producing network, started producing GFP 
immediately as expected. This expression decreased over the course of the experiment 
probably due to plasmid loss over time in vivo. Mice receiving our GFP producing 
bacteriophage particles began to produce GFP roughly 1 day post treatment but at a lower 
maximum than the positive control. This output dropped off at the same rate as our 
positive control despite a repeated treatment at day 3. The success of this proof-of-
concept delivery method should provide a roadmap for future in vivo experiments and 
open the door for new treatments that work with the microbiome to promote health or 
monitor disease status.  	  
	  	  
52 
 
Figure 3.10 – GFP Test Network Characterization.  
The GFP producing test network was tested for functionality alongside similar networks using the PLlacO 
promoter.  
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Figure 3.11 – GFP Bacteriophage Network Characterization.  
Bacteriophage particles carrying the GFP producing network were tested against EMG2 bacteria and 
screened for GFP expression compared to an uninfected EMG2 control.  
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Figure 3.12 – In Vivo Bacteriophage Delivery of GFP Producing Networks  
Fecal samples from positive control, negative control, and bacteriophage test mice were screened for GFP 
production over a 5-day period. Mice were given either bacteriophage particles or LB on days 1 and 3 and 
fecal samples were obtained daily. Bacteria from fecal samples were isolated and run on a FACS for GFP 
fluorescence. The number of GFP positive cells was determined by gating based on the negative control 
and compared to the total number of events.  
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3.4 – Impact and Discussion 
 The true goal of synthetic biology lies in providing real world applications that 
exist outside of the laboratory. In order to accomplish this however, once a synthetic gene 
network has been created and tuned it must be delivered to its target microenvironment, 
which can introduce a host of complications and problems. Although still in its 
adolescent years, it is important to make steps towards moving synthetic biology from the 
bench to the real world.  
Of particular interest for synthetic biology are medical applications, with a 
particular focus upon the body’s bacterial microbiomes. A wide host of bacterial 
microbiomes exists in and on the human body and some of these microbiomes have been 
shown to be very important for maintaining human health. Here we provided a proof-of-
concept for the delivery of a synthetic gene network to these microbiomes using 
lysogenic bacteriophage technologies and a gnotobiotic mouse model. We show that this 
technique allows for a gain-of-function of healthy bacteria that can be monitored through 
fecal samples. 
While this methodology allowed for the functionalization of bacteria in the gut 
microbiome, there are many ways it could be enhanced. First, since the bacteriophage 
genome carrying the synthetic network lacks any selection cassette, there is an 
evolutionary advantage for infected cells to attempt to discard the bacteriophage DNA. 
Current methods for avoiding plasmid loss focus upon expression of antibiotic resistance 
cassettes. This, however, is not feasible in a bacterial microbiome as the antibiotics 
required for plasmid selection would vastly disrupt uninfected cells. Therefore, future 
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networks could carry an addiction module (typically a toxin-antitoxin pair) that would 
increase plasmid longevity in target bacteria.  
Additionally our method focused upon targeting E. coli bacteria, which only 
account for a fraction of the total bacteria in the gut microbiome. Therefore, future 
approaches can focus upon synthetic network delivery through alternative bacteriophage 
infection, preferably those that can target multiple bacterial species. Unfortunately these 
bacteriophages have been poorly characterized, and therefore do not yet provide an easy 
tool for synthetic network delivery.  
Despite this, our methodology for functionalization of the gut microflora provides 
an exciting step towards synthetic biology based therapies. These therapies could change 
the standard of care for many various diseases, including inflammatory bowel disease and 
malabsorption disorders, by providing strictly regulated synthetic gene networks to 
microbiome bacteria and allowing localized treatment. Additionally, since this 
methodology does not target mammalian cells, unwanted side effects of this treatment 
affecting the host cells should be minimal to insubstantial.  
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Chapter 4 – ENGINEERING ANTIBACTERIAL PHAGEMIDS FOR 
TARGETED, NON-LYTIC BACTERIAL DEATH 	  
 4.1 – Overview 
 The emergence of antibiotic-resistant bacteria over the last few decades has led to 
higher instances of recurrent infection and mortality rates in clinical settings. As a 
substitute for antibiotics, bacteriophages have been used to combat bacterial infections 
through rupture of bacterial membranes or delivery of antibiotic-sensitizing networks.  
However, these treatments rely on the use of traditional antibiotics, which increase 
resistance prevalence, or cause lysis, releasing harmful toxins. As a result, a need exists 
to provide alternatives that can selectively target an infection while avoiding bacterial 
lysis and endotoxin release. Here, we engineer modular bacterial phagemids to express 
antibacterial proteins that inhibit intracellular bacterial processes leading to rapid, non-
lytic bacterial death. We show that this approach allows for iterative optimization, 
resulting in substantial killing of bacterial cells. Furthermore, this method can be used to 
target bacterial cells that harbor antibiotic resistance and obtains significant bacterial cell 
death in an in vivo mouse model. Together, this work introduces a dynamic and modular 
platform to trigger targeted non-lytic bacterial death in wild-type and antibiotic-resistant 
bacteria without reliance on traditional antibiotics. This platform provides a step towards 
real world treatment strategies that can be easily modulated to suit their target.  
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4.2 – Background 
Antibiotic-resistant bacterial infections are an increasing concern in clinical 
settings (Ruder et al.). Current first-line treatments rely upon traditional, small-molecule 
antibiotics to induce bacterial death and have resulted in the emergence of antibiotic-
resistance. Moreover, these treatments cause bacterial lysis and endotoxin release, 
producing symptoms ranging from diarrhea to sepsis, and result in off-target killing of the 
host’s normal microflora, allowing fungal pathogens and resistant bacteria to take 
advantage of a vacated niche (Dethlefsen et al.).  
A renewed interest has emerged for the use of bacteriophages to combat bacterial 
infections due to their ability to specifically target species of bacteria and deposit 
synthetically engineered gene networks. This provides a method for delivery of synthetic 
antibacterial networks, which are designed to disrupt bacterial structures and processes 
through expression of antibacterial or sensitizing genes (Clark and March). Historically, 
phage therapy has relied upon lytic bacteriophages, which cause bacterial death through 
rupture of the bacterial cell membrane (Lu and Collins) and release expressed proteins 
into the surrounding environment. This also results in unwanted release of bacterial 
endotoxins that can lead to detrimental side effects within the host. In contrast, lysogenic 
bacteriophages have their genome stably maintained within the cell, while mature 
bacteriophage particles become secreted without lysis. In previous studies, lysogenic 
bacteriophages have been engineered as an adjuvant to selectively sensitize bacteria to 
traditional antibiotics (Lu and Collins). However, this method still requires the use of 
traditional antibiotics to induce bacterial death and therefore does not address the 
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growing problem of antibiotic resistance. Furthermore, bacteriophage genomes can 
become unreliable over time due to fluctuations in copy number as the genome becomes 
packaged into viral particles, as well as resistance formation as the target cell tries to 
escape superinfection (Labrie et al.). This leads to decreased expression of a synthetic 
antibacterial network and increased bacterial survival.  
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4.3 – Antibacterial Phagemid Networks 
4.3.1 – Construction and Screening of Antibacterial Test Networks 
One way to address the limitations with bacteriophage is through phagemid 
technologies, which provide a method for targeted delivery of engineered antibacterial 
networks while ensuring sustained expression of antibacterial genes. This system allows 
for direct delivery of specific high copy plasmids to target cells, thereby ensuring protein 
expression levels and stability (Figure 4.1). The phagemid system relies upon expression 
of two plasmids. The first plasmid carries the desired synthetic network and 
bacteriophage packaging signal, while the second plasmid carries a phagemid helper 
system (Chasteen et al.), which produces the bacteriophage proteins required for particle 
assembly but is unable to be packaged into viral particles. Together, these plasmids result 
in the production of bacteriophage particles that selectively package an engineered 
plasmid harboring a synthetic gene network and a stable origin of replication rather than 
the bacteriophage genome. Therefore, this method avoids possible bacteriophage 
resistance formation as it averts bacteriophage particle replication and superinfection in 
target cells. As phagemids are inherently non-lethal, we design a deliverable synthetic 
gene network that would drive overexpression of non-lytic antibacterial proteins, which 
can be iteratively tested and optimized. This modular system induces non-lytic bacterial 
death without employing traditional antibiotics.  
We designed our phagemid system to be easily customizable by employing the 
plug-and-play cloning platform described by Litcofsky et al. This platform employs a 
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high copy plasmid that contains a large multiple cloning site (MCS). We cloned our 
antibacterial networks into this MCS and included the F1 origin of replication, which 
serves as the packaging signal for the well-characterized M13 bacteriophage (Russel et 
al.). This phagemid plasmid can be transformed into a production strain, carrying the 
M13cp phagemid helper plasmid, and phage particles produced by this strain can be then 
used to infect target Escherichia coli (E. coli) cells with our engineered plasmid, causing 
bacterial cell death (Figure 4.2). Our system allows for targeted delivery of a high copy 
plasmid, ensuring sustained expression of an antibacterial synthetic network, without 
producing the fluctuating gene expression seen in bacteriophage networks.  
In order to easily screen antibacterial networks that cause non-lytic bacterial cell 
death, we developed an antibacterial test network that expresses two antibacterial genes 
polycistronically under regulation of the tet-repressed PLtetO promoter. Synthetic design of 
the ribosome binding site (RBS) for each antibacterial gene allowed for independent 
control of expression levels (Salis et al.). Constitutive expression of the tetR repressor 
protein in the test and production strains inhibits gene expression, and its absence in 
target wild-type (WT) E. coli cells allows for strong antibacterial network expression. 
Five antibacterial peptides (ABPs), cecropin PR-39 (Boman et al.), apidaecin Ia (Li et 
al.), buforin II (Park et al.), dermaseptin (Jouenne et al.), and pleurocidin (Cole et al.), 
were selected for their ability to cause broad-spectrum non-lytic bacterial death (Brogden 
et al.) (Table 4.1). These ABPs were cloned into the MCS along with the PLtetO promoter, 
synthetic RBS, and terminator and were subsequently screened in the test strain, mgpro, 
for their ability to cause bacterial death following anhydrotetracycline (aTc) induced 
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expression (Figure 4.3). From these results we determined that cecropin PR-39 
(cecropin), which inhibits septum formation, DNA production, and protein production, 
and apidaecin Ia (apidaecin), which inhibits the enzyme DnaK and binds to bacterial 
lipopolysaccharide, were most effective at inducing bacterial death. Interestingly, the 
remaining ABPs tested did not induce bacterial death, possibly due to post-translational 
modifications or microenvironmental differences that our growth conditions could not 
replicate.  
4.3.2 – Construction and Screening of Antibacterial Phagemid Networks 
To examine the efficacy of cecropin and apidaecin as antibacterial therapeutics, 
we cloned these ABP networks into our phagemid system. After transforming into the 
phagemid production strain carrying the M13 helper plasmid, we collected the purified 
phagemid particles and screened them against the target bacterial strain (Figure 4.4). We 
found that treatment with phagemid particles harboring cecropin and apidaecin networks 
were able to produce a 2 to 3 logarithm (log) reduction of bacterial viability over the 
course of the experiment. This magnitude is similar to that of certain antibiotics, 
including beta-lactams such as ampicillin (Figure 4.5). In contrast, bacteriophage 
particles carrying the same ABP expression networks failed to produce the same level of 
bacterial death, instead recovering after four hours of infection. This highlights the 
unreliability of bacteriophage therapies and promotes resistance formation, which are 
both avoided through the use of phagemids. In order to target multiple intracellular 
processes and increase phagemid-induced bacterial death, we created combination 
networks using both ABP genes (Figure 4.6). Two of these networks (designated ϕI and 
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ϕII) expressed a singular copy of each ABP, while the final network (designated ϕIII) 
expressed two copies of each ABP with a PLtetO promoter driving each group. The 
combined phagemid networks had an enhanced effect upon the target bacteria, with the 
ϕIII network producing a 3.49 log reduction in bacterial viability.  
4.3.3 – Addition of Effector Networks 
Since cecropin and apidaecin both cause disruption of intracellular machinery, we 
further explored possible synergies by introducing various effector protein networks to 
the most effective phagemid system, ϕIII.  To this end we designed networks that either 
expressed lexA3 (Siliaty et al.), soxR (Nunoshiba et al.), csrA (Romeo et al.), or ccdB 
(Couturier et al.) genes. Each of these is thought to render bacteria more susceptible to 
bacterial death. LexA3 and SoxR proteins both inhibit the cellular response to oxidative 
stress, while the carbon storage regulator CsrA has been shown to restrict the supply of 
available energy resources to the cell. CcdB is a topoisomerase toxin, which interferes 
with DNA gyrase and results in the breakdown of bacterial DNA and cell death. The 
resulting phagemid particles were screened against the target bacteria (Figure 4.7).  
Interestingly, only the combined ABP-CcdB network showed increased bacterial death 
compared to the ϕIII control, resulting in a 4.04 log decrease in bacterial viability within 
the first two hours, whereas the other combined effector networks provided comparable 
or slightly diminished cell death compared to ϕIII.  
Due to the enhanced bacterial death with the addition of ccdB, we next chose to 
assess additional toxin networks that could produce non-lytic bacterial death. YeeV is a 
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toxin that inhibits cellular division by targeting two cytoskeleton proteins, FtsZ and MreB 
(Tan et al.). However, this dual inhibition causes cells to balloon and lyse. Inhibiting only 
FtsZ is accomplished by expressing a modified version of the YeeV protein truncated at 
the C terminus by 52 residues (designated YeeV’). This produces filamented cells that do 
not lyse (Tan et al.). The second toxin, ParE, acts by inhibiting DNA replication and 
converts supercoiled DNA to its linear form, causing filamentation and death (Jiang et 
al.). In addition to incorporating these toxin genes into new networks, two other networks 
were created employing the ccdB toxin gene. The first of these networks combined the 
ccdB toxin with the lexA3 effector while the second network overexpressed ccdB by 
employing two copies of the gene. These networks were cloned into our ϕIII plasmid. 
Purified phagemid particles were then tested against the target bacteria for bacterial death 
(Figure 4.8). The truncated YeeV toxin and the ParE toxin provided no additional 
bacterial death whereas overexpression of the CcdB toxin provided almost one full order 
of magnitude of increased bacterial cell death compared to ϕIII, obtaining a 4.45 log 
reduction in bacterial viability. This phagemid network was designated ϕCcdB. 
Surprisingly, the combined ccdB/lexA3 network to ϕIII (designated ϕCcdB+LexA3) did not 
result in additional effects on cellular death. This lack of synergy is likely explained by 
CcdB producing substantial DNA damage within the cell, making the contribution of 
LexA3 negligible (Bernard et al.). Taken altogether, our screen identified that the 
combined expression of two copies of cecropin PR-39, apidaecin Ia, and ccdB genes 
provide robust killing of target E. coli bacteria. 
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Figure 4.1 – Phagemid vs Bacteriophage Expression of a GFP Network  
Bacteriophage and phagemid particles carrying a constitutive GFP expressing network were purified and 
used to infect EMG2 bacteria. GFP expression was analyzed on a FACS machine at 2, 4, 6, and 22 hours 
and was compared to an uninfected EMG2 control.  
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Figure 4.2 – Overview of antibacterial phagemid construction  
Phagemid plasmids carrying an antibacterial network are transformed into the production strain, phagemid 
particles purified, and resulting engineered phagemids particles used to infect target bacteria, causing 
expression of antibacterial proteins resulting in non-lytic bacterial death. 	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Antibacterial Peptide Organism Size (AA) Mechanism of Action
Cecropin PR-39 Pig 39 Inhibits Septum Formation, DNA
Production, and Protein
Production
Apidaecin Ia Honeybee 18 Inhibits Enzyme DnaK and Binds
to Bacterial LPS
Buforin II Frog 21 Binds Nonspecifically to DNA
and RNA
Dermaseptin Frog 32 Inhibits DNA Production and 
Protein Production
Pleurocidin Flounder 25 Inhibits DNA Production and 
Protein Production 	  
Table 4.1 – Antibacterial Peptides  
A list of Antibacterial Peptides used in our ABP networks, including the organism they were characterized 
in, size, and mechanism of action.  
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Figure 4.3 – Screening Antibacterial Peptides in a Test Strain  
Five antibacterial expression networks were cloned into the testing strain, mgpro, and tested for bacterial 
cell death by induction with anhydrotetracycline (aTc), which relieves the inhibition of the PLtetO promoter 
by tetR. 
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Figure 4.4 – Screening Antibacterial Phagemid Networks  
Antibacterial phagemids and bacteriophage expressing either Cecropin or Apidaecin networks were tested 
against EMG2 E. coli.  
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Figure 4.5 – Ampicillin Treatment on EMG2 Bacteria 
Effects of ampicillin (50 µg/ml) against the E. coli strain EMG2 over time. 
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Figure 4.6 – Screening Combination Antibacterial Phagemid Networks  
Phagemids expressing combinations of antibacterial peptides were tested against EMG2 E. coli.  
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Figure 4.7 – Effector Network Addition to the ϕIII Antibacterial Phagemid Network and Screening 
Against Target E. coli  
(A) LexA3, soxR, csrA, and ccdB effector networks as well as ccdB, yeeV’, and parE toxin networks were 
cloned into the MCS of the ϕIII plasmid and purified particles were screened against EMG2 E. coli for 
possible synergy with cecropin and apidaecin networks. (B) Purified phagemid particles were tested 
alongside ϕIII particles for induction of bacterial death.	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Figure 4.8 – Toxin Network Addition to the ϕIII Antibacterial Phagemid Network and Screening 
Against Target E. coli 
A combined lexA3+ccdB expression network and overexpressing ccdB network were cloned into the MCS 
of the ϕIII plasmid. Purified phagemid particles were screened against EMG2 E. coli for their ability to 
cause non-lytic bacterial death. 	  
0 2 4 6 8 
ΦIII +
PLTetO T0 PLTetO T0
CcdB LexA3 
ΦIII +
PLTetO T0 PLTetO T0
CcdB
Lo
g 
su
rv
iv
al
-4
-2
0
2
0 2 4 6 
Lo
g 
su
rv
iv
al
-4
-2
0
2
Time (hours) Time (hours)
	  	  
74 
	  
4.4 – Screening against Resistant Bacteria 
Next, we sought to determine if our ϕCcdB phagemid network could be used to 
target antibiotic resistant bacteria. Three bacterial strains were created, each containing a 
plasmid with a different naturally occurring resistance to a common antibiotic class 
(ampicillin, chloramphenicol, and kanamycin respectively). Phagemid particles carrying 
the ϕCcdB network were then tested against these strains and compared to treatment with 
their respective chemical antibiotics (Figure 4.9). The phagemid-delivered ϕCcdB network 
was effective at targeting not only WT bacteria but also bacteria that harbored antibiotic 
resistances (obtaining bacterial death similar to that in WT cells). Together, our data 
show that the antibacterial phagemid delivery system is able to substantially kill WT and 
resistant bacteria independent of antibiotics.  
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Figure 4.9 – Antibacterial Phagemids Tested Against Resistant Bacteria 
ϕCcdB phagemid particles tested against EMG2 E. coli harboring plasmid-based resistances to either 
Ampicillin, Chloramphenicol, or Kanamycin antibiotics.	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4.5 – In Vivo Murine Peritonitis Model 
Lastly, we examined the validity of our system in vivo by employing a murine 
model for E. coli peritonitis (Domenech et al.). Seven-week-old C57Bl/6 female mice 
were given 106 colony forming units (CFUs) of the target bacteria, EMG2, via 
intraperitoneal (IP) injection. After 1 hour, mice were given IP injections of phagemid 
expressing antibacterial-toxin networks (Figure 4.10).  Mice were either given no 
treatment, an injection of phagemid particles that do not express any genes (vehicle 
group), or an injection of ϕCcdB or ϕCcdB+LexA3 particles. As expected from the in vitro 
experiments, both of the antibacterial phagemid treatments were highly effective at 
combating a lethal bacterial infection (Figure 4.11). Mice given either the ϕCcdB or 
ϕCcdB+LexA3 phagemid treatment had average survival above 80% over the course of our 
experiment, compared to 27% survival in our untreated group (p=0.0034 and p=0.0009 
respectively). The ϕCcdB/LexA3 antibacterial phagemid showed a similar survival advantage 
compared to the ϕCcdB phagemid, which suggests that lexA3 expression may be beneficial 
to bacterial cell death within a host. Our vehicle group had a survival of 58%. This 
survival advantage provided by phage particles has been previously reported (Duerkop et 
al.) and is associated with type I interferon and other proinflammatory gene induction 
upon exposure to phage capsid proteins. This increased inflammatory response provides a 
survival benefit to the vehicle group, resulting in increased survival compared to the 
untreated control. Regardless, the antibacterial phagemid groups had the highest survival 
rate, indicating that the antibacterial networks were able to enhance killing of the bacteria 
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in vivo.  Taken together, our results show that engineered phagemids are able to 
effectively target and kill E. coli in vitro and in vivo, without the use of antibiotics. 	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Figure 4.10 – Murine Peritonitis Infection Model Treated with Antibacterial Phagemids 
Overview of murine model for bacterial infection with EMG2 E. coli bacteria and phagemid treatment. 
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Figure 4.11 – In Vivo Murine Model Data 
Survival data for murine infection model with phagemid treatments and controls. Mice were divided into 4 
groups: untreated (n=22), vehicle only (n=12), ϕCcdB (n=10), and ϕCcdB+LexA3 (n=12). Data was obtained 
from two separate experiments.   
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4.6 – Impact and Discussion  
In this work we provide a generalized platform to produce non-lytic, bacterial cell 
death without reliance upon traditional antibiotics. By screening selected antibacterial 
peptides from the literature, alone or in combination with effector proteins and toxins, we 
were able to engineer a phagemid treatment that achieved a 4.45 log reduction in 
bacterial viability in vitro, was effective against WT and antibiotic-resistant bacteria, and 
resulted in over 80% survival in our in vivo experiments. While our approach relies upon 
the well-characterized M13 bacteriophage to create phagemids, similar systems can be 
applied to other bacteriophages as they become available. The modular nature of our 
system allows for the replacement of individual parts within its MCS to target specific 
bacteria. When a packaging signal becomes characterized for a desired bacteriophage, it 
could be swapped with the F1 origin of replication in our synthetic antibacterial 
phagemid and cloned into a production strain that expresses the proper phage proteins. 
This enables production of both targeted and broad antibacterial treatments, depending 
upon bacteriophage selection, and allows one to treat very specific bacterial infections 
such as V. cholera and S. aureus. Additionally use of bacterial phagemids reduces the 
risk of the target bacteria developing bacteriophage resistance. This allows for repeated 
treatment of bacterial infections without any loss of functionality.  
While some toxins had little effect on our target E. coli strain, all the selected 
toxins have a broad-range activity across many bacterial species (Couturier et al.; Jiang et 
al.; Mingorance et al.). Additionally, since our choices for antibacterial peptides and 
effector proteins are broad spectrum (Boman et al.; Li et al.; Siliaty et al.; Nunoshiba et 
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al.; Romeo et al.), this system should provide a plug-and-play therapeutic that can be 
easily modified to suit its target and will therefore function in many if not all target 
bacteria. Due to the stable nature of phagemids and decreased likelihood of resistance 
formation by reducing superinfection, this system provides a marked advantage for 
targeting bacterial infections over current bacteriophage techniques.  
Our engineered antibacterial phagemid platform is a step towards providing real-
world targeted treatment strategies through consistent expression of modular antibacterial 
networks, which have the ability to kill both specific strains as well as resistant bacteria 
without causing bacterial lysis. With recent discoveries regarding the benefits of bacterial 
microbiomes (Modi et al.; Kinross et al.), targeted therapies such as this, which do not 
rely on antibiotics, should provide an invaluable tool for treating bacterial infections and 
reducing the prevalence of resistant bacterial strains. The decreasing cost of DNA 
synthesis technologies over the past decade (Carlson et al.) and low cost of phagemid 
production should allow this platform to provide a cheap and effective therapy for 
bacterial infections in settings such as hospitals where growing bacterial resistances and 
healthcare costs are a problem (Gigi et al). 
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Chapter 5 – DISCUSSION AND CONCLUSION 	  
 In this work we have shown many large strides in the field synthetic biology 
starting from the ground floor. We started by creating a Plug-and-Play methodology for 
generating synthetic gene networks, which focused upon post-construction modifications 
and allowed for fast tuning and repurposing of genetic networks. This technique 
employed a large multiple cloning site that was composed of 31 unique Type IIp 
restriction sites and was contained within a cloning vector with a high copy origin of 
replication and an antibiotic resistance marker. In addition, a library of common genetic 
parts was optimized for use within the cloning vector for the construction of genetic 
networks. We showed that this method allowed for fast construction of genetic circuits by 
constructing a functional genetic toggle switch within 5 days of construction and 3 sets of 
3-day post-construction tuning. Additionally we showed that this methodology allows for 
repurposing of genetic networks by quickly creating two distinct feed-forward loop 
networks from elements found in the genetic toggle switch, which was made previously. 
This method for cloning allows for fast creation of functional synthetic gene circuits, 
which is a large improvement on previous construction techniques. The time and money 
saved with this methodology would allow the field of synthetic biology to spend less 
resources, time and money, constructing gene networks and focus more on testing and 
application.  
 Using this new construction method, we focused upon delivering functional gene 
circuits to target microbiomes for use in medical applications. To this end we created 
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several synthetic gene networks that either expressed an indole-converting enzyme, 
which was designed to convert indole to the blue-purple dye indigo, or the fluorophore 
GFP. These networks were inserted into the multiple cloning site found on the m13mp18 
plasmid, which allows for the production of M13 bacteriophage particles carrying the 
synthetic gene network. These bacteriophage particles were then used to functionalize the 
E. coli present in the gut mirobiome of a gnotobiotic murine model. We showed that this 
delivery method was successful at inducing gene expression in this microbiome by 
screening fecal samples for evidence network functionality. While this work only 
provides a proof-of-concept, it opens up many potential avenues for therapeutic design. 
Bacteria present in any human microbiome can be functionalized with genetic networks 
that are designed to sense disease states, such as rampant inflammation seen in Crohn’s 
disease, and secrete a therapeutic or diagnostic molecule, such as the anti-inflammatory 
cytokine IL-10. Not only would this allow for fast and tunable treatment of disease, it 
also allows for local delivery of therapeutics, which can be a marked benefit when 
compared to current systemic treatments that can result in unwanted off-target side 
effects. 
 Lastly, we showed that bacteriophage technologies could be used to cause 
targeted non-lytic bacterial cell death, without the use of traditional small-molecule 
antibiotics. By employing a phagemid system, we created phagemid particles that carried 
antibacterial synthetic gene networks that induced non-lytic bacterial death. These 
networks were combined with various effector and toxin networks to achieve 
approximately a 4.5 order of magnitude reduction in bacterial survival, a level that 
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exceeds certain antibiotics. Additionally, we showed that this method is effective against 
bacteria harboring resistances to commonly used antibiotics and is highly effective at 
combating an aggressive in vivo murine model for peritonitis. By employing phagemid 
technologies instead of bacteriophage, this system allows for targeted delivery of a high 
copy antibacterial plasmid, which ensures high expression levels of the antibacterial 
networks. Additionally since phagemid particles lack the ability to produce daughter 
particles, bacterial resistances to this method are slow to develop. This work provides a 
method for modular, targeted, and non-lytic bacterial death without reliance upon 
traditional antibiotics and may reduce the prevalence of antibiotic-resistant bacteria. 
 Synthetic biology is a vastly emerging field that offers many exciting tools for a 
variety of fields. This work highlights some of the potential applications that synthetic 
biology has to offer. As more complex synthetic gene networks become produced and 
additional genetic elements become characterized, the field should be able to provide 
almost limitless value for medicine, ecology, chemistry, and many other fields in both 
research and industry.  
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